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Leukemias are clonal diseases that commonly arise due to 
genetic lesions disturbing the regulation of blood cell develop-
ment and hematopoiesis. Proven reasons for leukemia, such 
as ionizing radiation, benzene, and cancer chemotherapy, are 
responsible for only a small portion of the total cases.1 The 
enhancing risk factors for leukemias are quantity and quality 
changes in folate metabolism.2
As a carrier of single-carbon fragments, folate is a vital 
nutrient for normal growth of mammalian cells. Folate plays 
an essential role in promoting purine and pyrimidine synthesis, 
especially in converting dUMP to dTMP (by 5-10-methylen 
tetrahydrofolate [THF] form). Folate is also essential  
for converting homocysteine to methionine and supplying 
methyl groups for methylation of DNA, RNA, proteins,  
neurotransmitters, and phospholipids (by 5-methyl THF 
form).3 5,10-Methylenetetrahydrofolate reductase enzyme 
(MTHFR: EC 1.5.1.20) catalyzes the irreversible reduction  
of 5-10-methylen THF to 5-methyl THF.
Methylenetetrahydrofolate reductase is an enzyme gene 
located on the short arm of chromosome 1 at 1p36.3. The 
cDNA sequence of this gene is 2.2kb long and is composed  
of 11 exons (103 to 432 bp).4 The major product of MTHFR 
locus in human is a 77-kilodalton protein, which is catalyti-
cally active, although a smaller 70-kilodalton isoform has also 
been observed in some tissues.
Several polymorphisms have been identified in this 
gene so far, among which 2 cases are shown to be of great 
significance in the literature. C677T polymorphism in exon 
4 leading alanine to be substituted by valine at codon 222 is 
the most frequently studied polymorphism in this gene. This 
allele is commonly named thermolabile because its activity 
decreases above 37°C.5 People with homozygous MTHFR 
677TT genotype have 30% enzyme activity compared with 
those having wild-type allele, while the enzyme activity is 
60% in people with heterozygous MTHFR 677 CT allele.4 
A C677T polymorphism causes amino acid change at the 
binding site of the MTHFR enzyme co-factor, flavin adenine 
dinucleotide (FAD). This polymorphism facilitates the sepa-
ration of the enzyme from its co-factor, and, as a result, the 
enzyme activity decreases.6 
Another important, well-studied polymorphism in the 
MTHFR gene is A1298C in exon 7, which causes glutamate 
to be substituted by alanine at codon 249.7 This polymor-
phism is located in the S-adenosyl methionine (SAM) regula-
tory domain. The binding of SAM to the MTHFR enzyme 
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leads to conformational changes within the structure of the 
enzyme and inhibits its activity, so the A1298C polymor-
phism also decreases the MTHFR activity though not so 
much as C677T.4 People with a 1298CC genotype do not 
show higher levels of serum homocysteine in comparison to 
the wild type people. However, like people with the 677TT 
genotype, those with the compound homozygous genotype 
for alleles C677T and A1298C show higher homocysteine 
and decreased folate in their serum.5 Locations of C677T  
and A1298C polymorphisms in the MTHFR gene are as far 
as 2.1kb from each other and are in tight negative linkage 
disequilibrium.8
Of course, other polymorphisms have been identified in 
the MTHFR enzyme coding gene such as the T1317C al-
lele, which does not change any amino acid into protein7 or 
G1793A allele resulting in argentine-to-glutamine substitution 
at codon 594. The association between these polymorphic 
alleles and enzyme activity has not yet been clarified. 
The correlation of the 2 main polymorphic alleles of the 
MTHFR gene, C677T and A1298C, with increased serum 
homocysteine, presents a higher risk of cardiovascular disease 
and birth defects, especially neural tube defects, coronary 
artery disease,4 cerebrovascular disease, venous thrombotic 
disease,9 squamous cell carcinoma,10 breast cancer,11 col-
orectal cancer,12,13 Turner Syndrome,14 endometrial cancer,9 
schizophrenia,15 and hypertension,16 which have been studied 
so far. Also several studies have been completed regarding 
the correlation between the presence of C677T and A1298C 
polymorphisms of the MTHFR gene and the risk of different 
leukemias that mostly indicate a lower risk of acute lymphoid 
leukemia (ALL) in people possessing 677TT variant.17,8,18 
However, the findings about this correlation in other acute 
and chronic leukemias are controversial.2,19-22
Since the majority of the previous studies have assessed 
the role of these polymorphisms in lymphoid leukemias, we 
decided to evaluate the 2 major MTHFR gene polymor-
phisms, C677T and A1298C, in myeloid leukemias (acute 
myeloid leukemia [AML] and chronic myeloid leukemia 
[CML]).
Materials and Methods
Our study population consisted of blood or bone mar-
row samples from 38 CML patients (male/female: 1.05, mean 
age 45.0 years, SD ± 16.7) and 106 AML patients (male/
female: 1.17, mean age 45.9 years, SD ± 14.7) who were di-
agnosed based on the detection of the BCR-ABL fusion gene 
by RT-PCR and immunophenotyping by flow cytometry, 
respectively. Also 97 healthy age- and sex-matched individuals 
(male/female: 0.94, mean age 44.8 years, SD ± 18.6) partici-
pated in this experiment as the control group. All patients had 
been referred to the Iranian Blood Transfusion Organization 
(IBTO) and Hematology-Oncology and Stem Cell Transplan-
tation Research Center of Shariati Hospital (Tehran, Iran) 
from 2007 through 2008. The Medical Ethics Committee of 
the Iran University of Medical Sciences (IUMS) approved the 
study (300MT) and written informed consent was obtained 
from all patients who participated in this study.
We analyzed MTHFR C677T and A1298C polymor-
phisms by the restriction fragment length polymorphism 
(RFLP) technique after PCR. Blasts and mononuclear cells were 
purified by Ficoll-Hypaque (Pharmacia LKB, Uppsala, Sweden) 
centrifugation, and their DNA was extracted through the 
standard method.23 The primers used to amplify the MTHFR 
gene were as follows: 
for C677T; forward primer 5ʹ-TGA AGG AGA AGG 
TGT CTG CGG GA-3ʹ and reverse primer 5ʹ-AGG ACG 
GTG CGG TGA GAG TG-3ʹ18 and for A1298C; forward 
primer 5ʹ-GCA AGT CCC CCA AGG AGG-3ʹ and reverse 
primer 5ʹ-GGT CCC CAC TTC CAG CAT C-3ʹ.8 The total 
reaction volume of 50 μL contained approximately 100 ng of 
DNA, 10 pmol of each primer, deoxynucleotide triphosphates 
(dNTPs), (10 mM each), 2.5 U of Prime Taq polymerase and 
reaction buffer (GENET BIO, Chungnam, South Korea), and 
ddH2O. Samples were amplified (Techne TC-512) using the 
following PCR conditions: 95°C for 5 minutes, 40 cycles of 
94°C for 30 seconds, 60°C for 1 minute, 72°C for 1 minute, 
and finally 72°C for 7 minutes. Amplification success was 
monitored by agarose electrophoresis. Afterwards the PCR 
products were subjected to digestion by Hinf1 and MboII 
(Fermentase) for C677T and A1298C polymorphisms, re-
spectively. The enzymatic mixture was composed of 0.1 μL 
restriction enzyme, 1 μL buffer, 13 μL PCR products, and 18 
μL distilled water and was incubated overnight at 37°C for 
both polymorphisms. After digestion, the enzymatic mixture 
was subjected to electrophoresis on 2% agarose.
In the case of C677T polymorphism, an undigested 198 
bp fragment showed wild type CC genotype, while 2 digested 
fragments of 175 and 23 bp showed mutant TT genotype, 
and 3 fragments of 198, 175, and 23 bp indicated heterozy-
gous CT genotype.18 
With regards to the A1298C polymorphism, this enzyme 
has 1 and 2 restriction sites on mutant and wild-type alleles, 
respectively. So wild-type AA genotype produces 3 digested 
fragments of 79, 37, and 29 bp, whereas mutant CC geno-
type generates 2 digested fragments of 108 and 37 bp, and 
heterozygous AC genotype produces 4 fragments of 108, 79, 
37, and 29 bp.8
Statistical Analysis
We assessed the association between the MTHFR geno-
type and the risk of hematologic malignancies by calculating 
the OR with a 95% CI using conditional logistic regression. A 
95% CI excluding 1.0 was considered statistically significant. 
Statistical analyses were carried out with the SPSS version 16 
(Chicago, IL) statistical software package.
Results
All 241 DNA samples (38 CML patients, 106 AML pa-
tients, and 97 healthy controls) were successfully genotyped 
by RFLP technique. Methylenetetrahydrofolate reductase 
genotyping among 97 healthy controls indicated a polymor-
phic allele frequency of 23.19% for C677T and 41.23% for 
A1298C.
Among the 106 adult AML patients in our study, the 
allele frequency of 677T was 26.88%. The frequencies of CT 
and TT genotypes in these patients were 36.79% and 8.49%, 
respectively, which did not show a statistically significant dif-
ference compared with those of the controls (OR=1.02, 95% 
CI: 0.57–1.8; OR=2.2, 95% CI: 0.65–7.6, respectively). 
Also, the 1298C allele frequency was 39.14% among AML 
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patients were 46.22% and 16.03%, respectively, which did 
not show a statistically significant difference compared with 
those of the controls (OR=1.33, 95% CI: 0.7–2.5; OR=0.75, 
95% CI: 0.34–1.6, respectively). 
For MTHFR 677 and 1298 among 38 CML patients par-
ticipating in our study, we observed allele frequencies of 22.36% 
and 43.42%, respectively. The frequencies of CT and TT geno-
types (for 677 allele) and AC and CC genotypes (for 1298 al-
lele) in CML patients were 28.94%, 7.89%, 50%, and 18.42%. 
None of the above-stated frequencies showed any statistically 
significant difference when compared to those of the controls 
(OR=0.7, 95% CI: 0.3–1.6; OR=1.75, 95% CI: 0.36–8.4; 
OR=1.7, 95% CI: 0.7–4; OR=1.03, 95% CI: 0.4–3). Distribu-
tions of genotype frequencies are listed in Table 1.
Discussion
The 677T allele of the MTHFR gene polymorphisms 
shows remarkable ethnic and geographical variation. In a 
study24 on 7000 newborns from 16 areas worldwide, the 
677T allele varied from 26.6% to 46% in Italy and 25.7% in 
the Middle East to 44.2% in northern China. Furthermore, 
in a study in Lebanon, the frequency of the MTHFR 677TT 
homozygous genotype was 7.66% and 13.08% in Muslims 
Arabs and Christians, respectively.25 These results indicate the 
presence of a selective pressure that causes such a geograph-
ical-ethnical pattern about the MTHFR 677T allele. In our 
study, 4.12% of the control samples had a mutant homozy-
gous MTHFR 677TT genotype, and the frequency of allele T 
was 23.19%.
Analysis of the control group in our samples showed a 
rather low frequency of MTHFR C677TT polymorphism 
among the Iranian population when compared to other Asian 
populations, especially eastern countries.5,11,26 Like C677T, 
the MTHFR A1298C polymorphism also shows remarkable 
geographical-ethnical variation. Most of the Asian studies 
showed a frequency range of 15% to 20% for the 1298C 
allele.9,10,20,27 Our results showed the allele frequency of 
41.23% for MTHFR 1298C in the Iranian population, which 
seems much higher than other Asian reports. Such a high 
frequency for the A1298C allele has already been reported 
among Iranians28 as well as among the Lebanese and the 
Jewish population of the Middle East.29,30 In addition, the 
frequency of homozygous 1298CC genotype in our study was 
calculated to be 22.68%, which seems very high and is com-
parable with the results in the Lebanese population of 23.9% 
by Sabbagh and colleagues.29 
Multiple studies about the role of the 2 C677T and 
A1298C polymorphisms of the MTHFR enzyme gene in leu-
kemia have been completed. Skibola and colleagues18 observed 
that people with MTHFR 677 TT, 1298AC, and 1298CC 
genotypes, compared with wild-type genotypes, have a lower 
risk for developing ALL (a 4.3-, 3-, and 14-fold decrease, re-
spectively, the last of which was not statistically significant). 
No significant difference between MTHFR genotypes distri-
bution among AML patients and control groups was observed 
in this study, suggesting that MTHFR gene polymorphisms 
have not influenced the risk of AML.
In another study, Wiemels and colleagues8 assessed the 
influence of MTHFR polymorphisms on 3 subgroups of 
pediatric leukemias including infant lymphoblastic or myelo-
blastic leukemias with MLL rearrangements and childhood 
lymphoblastic leukemias with either TEL-AML1 fusions or 
hyperdiploid karyotypes. They found that MTHFR 677 vari-
ants (CT and TT genotypes) were associated with a lower risk 
of leukemias with MLL rearrangements, while the 1298CC 
genotype induced a lower risk of hyperdiploid leukemias. Also 
in this study, no association was observed between MTHFR 
polymorphisms and myeloid leukemia. A smaller study in 
Brazil17 on pediatric ALL also showed the MTHFR 677T al-
lele conferred a 2.4-fold decrease in the risk of ALL, while the 
A1298C genotype did not affect the risk of ALL.
There are few studies about the role of MTHFR poly-
morphisms in developing chronic leukemias, especially CML. 
In the Moon and colleagues study20 the MTHFR 1298CC 
genotype was strongly associated with the risk of CML in the 
Korean population, while the 677TT allele did not affect the 
risk of CML. In this study the MTHFR 1298CC genotype 
was higher than the controls in AML and multiple myeloma 
patients, although the difference was not statistically signifi-
cant. In Brazil, Barbosa and colleagues2 also did not find any 
significant association between MTHFR polymorphisms and 
CML/AML M3 leukemias.
Table 1_Association Between MTHFR C677T and A1298C Genotypes and AML/CML
Polymorphism AML cases OR 95% CI CML cases OR 95% CI  Control
C677T 
CC 58 (54.71%) 1          — 24 (63.15%) 1       — 56  (57.73%)
CT 39 (36.79%) 1.02* I  (0.57–1.8) 11 (28.94%) 0.7 I   (0.3-1.6) 37  (38.14%)
TT 9   (8.49%)  2.2 I    (0.65–7.6) 3   (7.89%) 1.75 I (0.36-8.4) 4    (4.12%)
Allele frequency of T 26.88%  22.36%  23.19%
A1298C
AA 40 (37.73%) 1         — 12 (31.57%) 1       — 39  (40.2%)
AC 49 (46.22%) 1.33 I  (0.7-2.5) 19 (50%) 1.7 I   (0.7-4) 36  (37.11%)
CC 17 (16.03%) 0.75 I  (0.34-1.6) 7   (18.42%) 1.03 I (0.4-3) 22  (22.68%)
Allele frequency of C 39.14%  43.42%  41.23%
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In another study about the relationship between 
MTHFR polymorphisms and the risk of relapse after he-
matopoietic cell transplantation for CML, a 2- to 4-fold de-
crease was observed in the relapse risk of patients with variants 
of both polymorphisms (which was statistically significant 
for only the 1298C allele).19 This decreased risk seems to be 
independent of the undesired effects of the 1298C allele of 
CML mentioned in the Moon and colleagues study.20 Larger 
nucleotide sources (as a result of the lower activity of the 
MTHFR enzyme) may have caused more genetic stability in 
transformed cells. These may affect the acquiring additional 
genetic changes and lead to the progression from BCR-ABL 
positivity to clinical relapse.
Among the results standing in contrast with the afore-
mentioned studies, the Hur and colleagues study21 took notice 
that no relation was found between MTHFR C677T variants 
(CT and TT) and CML, AML, and ALL development, while 
the MTHFR A1298C variants (AC and CC) were reported to 
decrease the risk of AML and CML. However, Deligezer and 
colleagues22 observed a similar pattern in the distribution of 
the MTHFR C677T polymorphism in myeloid and lymphoid 
leukemias, in such a way that the frequency of the MTHFR 
677TT genotype in all 3 malignancies of CML, AML, and 
ALL was lower than those of the controls, although the dif-
ferences were not statistically significant. In our study, we did 
not find any statistical significant association between the dis-
tribution of MTHFR polymorphisms (C677T and A1298C) 
in myeloid leukemias (AML and CML) and the control 
group. This indicates that the presence of the polymorphisms 
did not affect the risk of AML and CML among our samples.
Despite some incompatible results, the hypothesis can be 
suggested that imbalanced intracellular distribution of folate 
metabolites caused by MTHFR variants may affect the risk 
of lymphoid leukemias but not myeloid leukemias. Acute 
lymphoid leukemia and AML are clinically different diseases 
arising from distinct cell lineages and also show differences in 
response to treatment. Methotrexate as an antifolate is an ef-
fective chemotherapy agent for the treatment of ALL, while it 
is not as successful with AML. It is due to a higher expression 
of Folypolyglutamate synthetase (FPGS) in lymphoid cells 
than myeloid ones. Folypolyglutamate synthetase catalyzes the 
formation of long-chain folate and antifolate polyglutamate 
derivatives. This different expression is also seen in normal 
lymphoid and myeloid progenitor cells.18 In fact, these differ-
ences are indicators of the probable higher folate requirement 
of lymphoid cells and subsequently more susceptibility to 
folate deficiency and DNA damages than myeloid cells. Of 
course, it should be considered that most of the studies done 
so far about the relationship between MTHFR gene polymor-
phisms and leukemias have not assessed the dietary folate in-
take in their samples, so the effect of folate level has not been 
completely clarified yet.
In experimental models of folate shortage, the misincor-
poration of uridylate in the DNA structure increases to as 
many as 100 times. This situation enhances the probability of 
the occurrence of double strand breaks in the DNA molecule 
up to 50 times.9 This model can justify the role of genetic 
instabilities in malignancies.
However, in a study about the effects of MTHFR poly-
morphisms and dietary folate intake in colorectal cancer risk, 
it has been found that people with the MTHFR 677TT geno-
type with a normal folate level in their plasma have a lower 
risk of colorectal cancer compared with those with 677CC 
genotype.31 Interestingly, consuming alcohol 5 or more times 
per week diminishes the lower cancer risk.12 In fact, the as-
sociated risk of malignancies with MTHFR polymorphisms 
shows a gene-nutrient pattern that strongly depends on the 
folate intake level. Since MTHFR variants are risk factors for 
some cancers, such as cervical, breast, esophageal, and gastric 
malignancies,20,27 it is well understood that MTHFR poly-
morphisms can play different roles in these disorders depend-
ing on the organs involved and the environmental situations.
Decreased activity of MTHFR enzyme causes an el-
evation in its substrate levels (5-10-methylen THF) and 
subsequently promotes more methylation of uridylate to thy-
midylate. On the other hand, a decreased 5-methyl THF pool 
(the product of enzymatic reaction) may affect DNA methyla-
tion and thereby contribute to tumor genesis.
Concerning these facts, in the case of colorectal cancer 
decreased activity of the MTHFR enzyme leads a shifting of 
the normal pattern of intracellular folate storage toward more 
DNA stability (protective role), while in the cases of cervical 
or breast cancers, decreased activity of the MTHFR enzyme in 
some tissues likely shifts more toward hypomethylation result-
ing in oncogenes activation and susceptibility to malignancies 
(adverse effects).20 Supporting this hypothesis, it has been 
shown that MTHFR knockout mice have neuropathological 
lesions, aortic lipid deposition, and DNA hypomethylation.32 
In addition, these incompatible results can be associated with 
the presence or lack of folate deficiency, different types of 
malignant cells (solid tumors/hematologic malignancies or 
acute/chronic leukemias or lymphoid/myeloid lineages), and 
ethnical differences.
As stated in previous studies,4 MTHFR enzyme activity 
should not be considered as the only effective factor in folate 
metabolism pathways. Intake of several elements in a nutri-
ent diet, such as vitamins B6 and B12, which are co-factors 
of serine hydroxymethyltransferase (SHMT) and methionine 
synthase (MS) enzymes, respectively, can influence the folate 
metabolism. Flavin adenine dinucleotide as MTHFR co-factor 
is a form of vitamin B riboflavin, and it has been suggested 
that the riboflavin status may play a role in the optimal func-
tion of the MTHFR enzyme. Excessive use of alcohol, which 
causes folate and vitamin B family deficiencies, must also be 
considered as an effective environmental factor. Different vari-
ants of all the above-stated enzymes may contribute to the risk 
of DNA instability and tumor genesis.
In conclusion, the present study showed no relation 
between MTHFR polymorphisms and myeloid leukemias 
(AML and CML), but further studies on larger samples with 
determined biochemical profiles (such as folate situation and 
homocysteine level) are necessary before absolute judgment 
about the role of MTHFR polymorphisms in the develop-
ment of myeloid leukemias. Also, the high frequency of the 
1298C allele in the Iranian population can be considered in-
teresting points of our results.  LM
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